Skip to content
Search

Latest Stories

Bangor University greenlights new Pharmacy degree for September 2025; support regional health and wellbeing

Bangor University greenlights new Pharmacy degree for September 2025; support regional health and wellbeing
As Bangor University expands its Medical School, it adds a new Pharmacy degree aimed to provide local students with opportunities to meet healthcare demands

In latest updates, Bangor University has given the go-ahead for a new pharmacy degree starting September 2025.

The four-year Master of Pharmacy( MPharm)undergraduate degree programme is the primary route that students take to become pharmacists and will be offered in Welsh language.


The programme is part of the institution's strategy to provide opportunities for local applicants encouraging them to pursue vital fields and ensure they meet the healthcare workforce demands in North Wales and beyond.

The new provisionally GPhC-approved MPharm degree, set to open registrations for the September-intake, is under the new North Wales Medical School and offers Pharmacy alongside Medicine and allied Health programmes.

The programme will be provisionally accredited until the accreditation process is complete.

Aligning with the GPhC’s new Standards for Initial Education and Training of Pharmacists, the MPharm programme aims to support the regional health and wellbeing of the population by preparing pharmacy graduates as part of integrated healthcare teams to facilitate patient care.

Bangor University offers significant experiential teaching through partnerships with the Betsi Cadwaladr University Health Board (BCUHB), community pharmacies, GP practices, and Health Education and Improvement Wales (HEIW).

Moreover, in partnership with BCUHB, Bangor University aims to be the foremost provider of quality pharmacy education in North Wales.

According to the University, stakeholder involvement is central to the philosophy of the MPharm programme structure.

With core pillars focusing on The Patient, The Pharmacist, and The Health Care System, these will be integrated into ‘Patients, their Medicines and their Care (PMC)’ modules that students will follow.

Prof Stephen Doughty, Head of Pharmacy Programme at Bangor University, said, “This programme will meet both a local and national need and will ensure that North Wales has a strong base for pharmacy education and research.

"This will ensure that patients and potential students’ needs are being met for the future.”

Lois Lloyd, Chief Pharmacist at Betsi Cadwaladr University Health Board, said: “I’m delighted with this positive news for North Wales and we look forward to working in partnership with Bangor University to support the programme.

"We now have an opportunity to locally invest in the training of pharmacists in North Wales and to develop the clinically skilled workforce we, and the wider NHS, need for the future.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less